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Objective. The current study addresses the nature of memory difficulties in amnestic Mild 
Cognitive Impairment (aMCI). Whereas recollection is consistently found to be impaired in 
aMCI, the results regarding familiarity are divergent. One potential factor that could explain 
this divergence in findings relates to heterogeneity of aMCI patients, so that only those aMCI 
patients who are to develop AD may present with impaired familiarity. The present study 
aimed at testing this hypothesis.  
Methods. A group of 45 aMCI patients and a group of 26 healthy older adults performed a 
verbal recognition memory test with the Remember/Know paradigm to assess recollection and 
familiarity processes. All participants were followed for 4 years with clinical and 
neuropsychological testing. At the end of the follow-up, 22 aMCI patients progressed to AD 
and 23 aMCI patients remained stable. Initial memory performance was compared between 
the three groups.  
Results. Whereas recollection was severely diminished in all aMCI patients, familiarity 
accuracy (and consequently global recognition accuracy) was found to be impaired only in 
aMCI patients who subsequently developed AD.  
Conclusion. These findings suggest that the enrichment of aMCI population with 
predementia stages patients may modulate the likelihood to observe familiarity deficits, and 
impaired global recognition accuracy may accompany incipient Alzheimer’s disease. 
 






Familiarity in Mild Cognitive Impairment as a function of patients’ clinical outcome four 
years later 
Introduction 
Amnestic Mild Cognitive Impairment (aMCI) designates the presence of progressive memory 
deficits in individuals who are not demented and who retain relatively normal activities of 
daily living 1. Given that patients with aMCI are at high risk of developing Alzheimer’s 
disease (AD) 2,3, this syndrome has attracted considerable interest as it can inform about the 
predementia stage of AD. In particular, clinicians need a finer characterisation of memory 
deficits in aMCI that would qualify as an early cognitive marker of Alzheimer’s disease. 
 To this end, the most promising distinction concerns recollection and familiarity 4, for a 
review which designate the processes that subserve recognition of past experience. Recollection 
is defined as the conscious retrieval of the event together with contextual details from the 
encoding episode. It allows a rich remembering of what happened, where and when, 
accompanied by the feeling of reliving mentally the past event. For instance, remembering 
that we went to a barbecue at Paul and Joan’s place last Saturday night and that it was a warm 
night is a case of recollection. In contrast, familiarity is conceived as an acontextual sense of 
prior occurrence. It allows the rapid recognition of people, objects and places that we 
previously encountered, and is accompanied by a feeling of knowing. For example, when we 
see a face in the bus, we can have the strong feeling that we have met this person before even 
if we cannot tell when and where. Impaired recollection was consistently observed in aMCI 
patients. However, the studies failed to reach a consensus regarding the fate of familiarity, as 
there were almost as many reports of impaired familiarity in aMCI as reports of preserved 
familiarity 5,6. Given that impaired recollection associated with preserved familiarity can be 
observed in several populations including healthy older adults 7 and frontotemporal dementia 
8, it is important to determine whether familiarity is actually affected or not in the early course 
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of AD as this could be a deficit specific to AD. Theoretically, given that the earliest site of 
neurodegeneration in AD is the transentorhinal cortex 9 and considering the critical role of 
this region in familiarity 10, it is likely that impaired familiarity represents the initial memory 
dysfunction in the course of AD. Actually, it may be the only subtle memory deficit in the 
preclinical stage of AD 11. Next, with the rapid progression of neurodegeneration in the 
hippocampus and retrosplenial hypometabolism and atrophy, recollection deficits should 
accompany, and even dominate over, familiarity deficits in aMCI due to AD 11. 
 One critical factor that could explain the divergence in findings regarding familiarity 
in previous work concerns heterogeneity of the MCI population. Given that only a portion of 
aMCI patients is actually harboring an Alzheimer pathology, the emergence of a familiarity 
deficit may depend on the degree of enrichment of the aMCI sample with prodromal AD 
patients. Currently, only indirect evidence suggest that familiarity may indeed be impaired 
particularly in those aMCI patients who have the highest likelihood to progress to 
Alzheimer’s disease. In a meta-analysis, Koen and Yonelinas 5 observed an effect size close 
to zero in single-domain aMCI indicating no decrease in familiarity, but a marginally 
significant effect size in studies including both single-domain and multiple-domain aMCI. As 
multiple-domain aMCI patients demonstrate typically a higher rate of progression to AD 12, 
this may be taken as indirect support to the idea of familiarity deficits as early cognitive 
marker of AD. Moreover, Wolk et al. 13 found that familiarity scores in a group mixing aMCI 
patients and healthy controls correlated with the “AD cortical signature”, a measure of 
decreased cortical thickness across frontal, parietal and temporal regions that is sensitive to 
early AD 14,15.  
 In order to test the hypothesis that impaired familiarity-based memory occurs only in 
aMCI patients who are in an early stage of AD, the current medium-term longitudinal study 
retrospectively analysed recollection and familiarity performance in aMCI patients as a 
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function of the clinical outcome at the end of a 4-year neurological and neuropsychological 
follow-up. In aMCI populations, follow-up assessments have long been the preferential way 
to reveal the aetiology behind the MCI symptomatology. Even though aMCI is a frequent 
precursor of AD, follow-up evaluations also reveal variable outcomes, including stability of 
symptoms, return to normal cognition, evidence of psychiatric conditions and progression to 
non-AD dementia 16,17. In this study, aMCI patients performed an episodic memory task in 
which the contribution of recollection and familiarity was estimated by means of the 
Remember/Know paradigm 18,19. Then, patients were followed with neurological exams and 
neuropsychological assessments for up to 4 years. At the end of the follow-up period, patients 
were classified as a function of whether they developed clinically probable AD or were still 
diagnosed as aMCI and their recollection and familiarity estimates were compared according 
to this clinical outcome. In line with the idea that alterations of familiarity should be 
characteristic of early AD 13, we hypothesized that familiarity should be impaired compared 
to controls only in those aMCI patients who developed AD in the subsequent years. In 
contrast, recollection should be impaired in all patients as this function is sensitive to several 
conditions that could be associated with mild cognitive impairment 20,21.  
   
Methods 
Participants 
The initial patient group consisted of 47 participants (21 women) who met the Mayo Clinic 
criteria for amnestic MCI 2 at inclusion. During follow-up examinations, the patients were re-
evaluated with a neuropsychological battery and a neurological assessment. In the course of 
the follow-up, one patient died one year after inclusion and one patient was eventually 
diagnosed with progressive supranuclear palsy, so the data from both patients were excluded 
from the current analyses (final data set n = 45). Twenty-two aMCI patients met the clinical 
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diagnosis of Alzheimer’s disease 22 6 to 42 months after inclusion (MCI-AD, mean time to 
conversion: 21.4 months ± 11.4), and 23 patients still presented with aMCI 4 years after 
inclusion (stable MCI).  
A control group of 27 healthy elderly participants (18 women) also participated in the 
study. At inclusion, subjects in this group had no cognitive or psychiatric problems, were free 
of medication that could affect cognitive functioning, and reported being in good health. 
During follow-up, 1 participant demonstrated cognitive decline compatible with a 
degenerative process and was therefore excluded from the analyses.  
All three groups performed several neuropsychological tests assessing short and long-term 
memory and executive functioning (Table 1) and biomarkers of neurodegeneration were 
obtained to further characterize MCI patients. Structural neuroimaging (3D T1-weigthed 
image) was performed in 19 MCI-AD patients, 18 stable MCI patients and 22 controls. 
Cerebral glucose metabolism was measured with FDG-PET in 22 MCI-AD patients, 23 stable 
MCI patients and 26 controls. Group comparisons with SPM (for details about image analysis 
methods, see 23) indicated that, compared to controls, MCI-AD patients showed significant 
hypometabolism in the posterior cingulate, temporo-parietal and lateral temporal cortices. 
They also demonstrated atrophy in the hippocampus as well as in parietal, temporal and 
frontal regions. Stable MCI patients had poorer metabolism in the posterior cingulate cortex 
compared to controls and hippocampal atrophy. This pattern of cerebral changes is consistent 
with previous reports in MCI 24-26. For some participants (19 MCI-AD, 17 stable MCI and 11 
controls), the presence of at least one ɛ4 allele of APOE genotype was searched for via blood 
samples (Table 1). There was no difference in the proportion of carriers between MCI-AD 
and stable MCI patients, χ2 = .11, p = .73. 
According to the Declaration of Helsinki, all participants gave their written consent to 




Materials and procedure 
All participants were tested individually. The experimental episodic memory task was adapted 
from Souchay et al. (2007). In the study phase, participants were presented with 20 cue-target 
pairs of French words in the centre of a computer screen. The cue word was printed in 
lowercase letters next to the target word, which was printed in capital letters. The two words 
were weakly associated. Participants were instructed to try and remember the pairs because 
their memory for the second (target) word would later be tested by using the first word as a 
cue. The pairs were shown in random order and each remained on the screen for 5 seconds. 
After a short delay filled with instructions, the cued recall phase began. The cues were 
presented in random order. The participants were asked to recall the target word that was 
associated with each cue during the study phase. They had next to give a feeling-of-knowing 
judgement, indicating whether they thought they would be able to recognise the target in a 
later forced-choice recognition test (data not analysed here). 
Finally, a five-alternative forced-choice recognition phase was administered. Each of 
the 20 target words was presented with 4 semantically related distracter words. The 
participants had to indicate which word they had seen in the study phase. Moreover, for each 
response, they were asked to give a Remember/Know/Guess judgement. Participants were 
instructed that a Remember response corresponded to the recollection of specific information 
relative to the stimulus encoded at the study phase; that a Know response referred to 
recognition on the basis of familiarity without recollection; and that a Guess response could 







Analyses of variance (ANOVAs) were used to assess between-group differences (Group: 
MCI-AD, stable MCI, controls) on neuropsychological measures and on episodic memory 
measures: proportion of correct cued recall, proportion of correct recognitions, proportions of 
Remember, Know and Guess responses to targets and distractors, and dual-process signal 
detection model estimates of recollection ([proportion of Remember responses to hits minus 
proportion of Remember responses to false recognitions]/[1 - proportion of Remember 
responses to false recognitions] 27) and familiarity (d-prime based on the Independent 
Remember/Know procedure, where the familiarity score for hits and false recognitions is 
given by the proportion of Know responses/[1 – proportion of Remember responses] 28). 
An additional analysis assessed which memory scores (cued recall, recognition 
memory, recollection and familiarity estimates) best classify individuals as belonging to MCI-
AD or stable MCI using a stepwise discriminant function analysis. 




The demographic and clinical characteristics at inclusion of the final three groups are 
presented in Table 1. The MCI-AD, stable MCI and control groups were matched in terms of 
age, education, vocabulary abilities (Mill Hill test 29) and scores on the Geriatric Depression 
Scale 30. The MCI-AD patients had a poorer score on the Mattis Dementia Rating Scale 31 
than stable MCI patients, who themselves performed more poorly than controls, F(2, 68) = 
21.3, p < .001. The comparison of neuropsychological scores across the three groups (Table 
1) showed that MCI-AD patients were significantly impaired compared to stable MCI and 
controls, whose scores did not differ significantly, in working memory, executive functioning, 
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continuous recognition memory, and recent autobiographical memory (of note, for the latter, 
stable MCI nevertheless showed a medium-size difference with controls, d = 0.79). Both MCI 
groups were equally impaired in remote autobiographical memory. Awareness of memory 
problems was also affected in MCI-AD patients, as they underestimated their difficulties as 
compared to stable MCI patients and controls. 
Scores for the episodic memory task for each group are presented in Table 2. The ANOVA 
comparing cued recall performance between the three groups showed a significant and large 
group effect, F(2, 68) = 12.59, p < .001, ƞ2p = .27. Post-hoc Tukey’s HSD tests revealed 
differences between all three groups (ps < .05), indicating that cued recall performance was 
poorer in MCI-AD patients than in stable MCI patients (d = 0.87) and controls (d = 1.52), and 
that stable MCI patients had impaired performance compared to controls (d = 0.62). 
The ANOVA on the proportions of correct recognition responses in the 5-alternative 
forced-choice test revealed a significant and large effect of group, F(2, 68) = 14.83, p < .001, 
ƞ2p = .30. Tukey’s HSD tests showed that MCI-AD patients had poorer recognition 
performance than both stable MCI patients and controls (ps < .01, d = 1.10 and 1.64 
respectively), whereas stable MCI patients showed a medium-size difference with controls (d 
= 0.51) that did not reach statistical significance (p = .15).  
For Remember responses, the ANOVA on hits indicated a large effect of group, F(2, 
68) = 15.48, p < .001, ƞ2p = .31. Both MCI-AD and stable MCI reported less Remember 
responses to targets than controls (ps < .01, d = 1.78 and d = 0.83 respectively), and MCI-AD 
classified targets as Remember less often than stable MCI (p = .08, medium effect size, d = 
0.83). The ANOVA on false recollections did not reveal any significant effect (F(2, 68) = 
1.35, p = .26, ƞ2p = .03). Notably, there were very few false recollections.  
For Know responses, the ANOVA on hits yielded a medium-size non-significant 
group difference, F(2, 68) = 2.51, p = .08, ƞ2p = .06. Two-by-two effect size of group 
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comparisons suggested that both patients groups were comparable (d = 0.10) and provided 
slightly more Know responses to hits than controls (MCI-AD versus controls, d = 0.58 and 
stable MCI versus controls, d = 0.59). Also, there was a significant and medium effect of 
group on false recognitions accompanied by a Know judgment, F(2, 68) = 3.50, p < .05, ƞ2p = 
.09. Post-hoc tests pointed to an abnormal rate of false Know responses in MCI-AD (p < .05, 
MCI-AD versus controls, d = 0.88), whereas stable MCI showed a medium-size non-
significant difference with controls (p = .17, d = 0.58). 
For Guess responses, there was no group difference in the proportion of Guess 
response given to targets, F(2, 68) = .40, p = .66, ƞ2p = .01. In contrast, the ANOVA on Guess 
responses to distractors yielded a significant group difference, F(2, 68) = 6.66, p < .01, ƞ2p = 
.16. Post-hoc tests showed that MCI-AD patients produced more Guess responses to 
distractors than the other two groups (ps < .05, MCI-AD versus controls, d = 0.99; MCI-AD 
versus stable MCI, d = 0.72), which did not differ (p = .57, d = 0.27). This may indicate that 
Guess responses reflected more often total absence of memory in MCI-AD patients, whereas 
controls and stable MCI patients may have used Guess responses for unconfident answers. 
The ANOVA on recollection estimates showed a large group effect, F(2, 68) = 16.25, p < 
.001, ƞ2p = .32. Recollection was impaired in both MCI groups, with a significantly larger 
deficit in MCI-AD patients than in stable MCI patients (Tukey’s HSD tests, p < .05 for all 
comparisons; MCI-AD versus controls, d = 1.69; MCI-AD versus stable MCI, d = 0.80; stable 
MCI versus controls, d = 0.78). Finally, the ANOVA on familiarity estimates (d-prime) 
revealed a significant and medium effect of group, F(2, 68) = 7.70, p < .05, ƞ2p = .12. Post-
hoc Tukey’s tests indicated that only MCI-AD patients had significantly largely impaired 
familiarity accuracy (p < .05, MCI-AD versus controls, d = 0.85). In contrast, stable MCI 
patients’ familiarity performance did not differ from that of controls (p = .14, d = 0.49). Of 
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note, both MCI subgroups did not differ (p = .52, d = 0.42), suggesting that stable MCI 
patients performed in-between MCI-AD patients and controls. 
The results of the stepwise discriminant function analysis indicated that the best predictor 
of group membership was the recognition memory score, while the other scores did not 
significantly improve the model (Wilk’s λ = 0.77, p < .001). Recognition memory scores 
correctly classified participants with 72% sensitivity, 69% specificity and 71% total accuracy. 
Figure 1 illustrates the distribution of recognition scores in the three groups. 
 
Discussion 
If a patient with aMCI consults at the memory clinic, can an investigation of recollection and 
familiarity help to refine his/her prognosis? Past research has unanimously reported impaired 
recollection, but has been divergent with regard to familiarity. In the current study, we tested 
the hypothesis that impaired familiarity should be seen especially in those aMCI patients who 
actually progress to Alzheimer’s disease in the subsequent years. This prediction relies on the 
fact that initial neurodegeneration in the course of Alzheimer’s disease affects the 
transentorhinal cortex, which is thought to support familiarity 11,13,32. More precisely, when 
the symptomatic stage of MCI-due-to-AD is reached, patients should present with impaired 
familiarity associated with pathology in the transentorhinal cortex as well as severe 
recollection deficit due to the widespread pathology to regions underlying this function 11. 
 The main finding of the study was that aMCI patients who presented the clinical 
symptoms of Alzheimer’s disease within 4 years of follow-up (i.e., MCI-AD) had impaired 
familiarity accuracy at baseline when compared to healthy older controls. The deficit emerged 
mainly as an increased rate of false recognitions based on familiarity, indicating a misleading 
reliance on familiarity rather than a reduction in the frequency of its use. In contrast, aMCI 
patients who were stable after 4 years showed small-to-medium-size non-significant decrease 
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of familiarity compared to controls. Moreover, both aMCI groups had severely impaired 
recollection, more so for aMCI patients who developed AD. The other measures of the task 
align with this pattern: cued recall (which is more similar to recollection than to familiarity) 
was much diminished in both aMCI groups, with the largest deficit in MCI-AD. Global 
forced-choice recognition scores were largely deficient in MCI-AD, as was also continuous 
verbal recognition memory in the additional test battery. Discriminant analysis showed that 
recognition memory was the best predictor of subsequent AD in MCI. 
In dual-process models of recognition memory, accurate global recognition memory 
usually necessitates the efficient and independent contribution of both recollection and 
familiarity 4. So, the severe impairment of recognition memory observed in MCI-AD is 
consistent with the fact that both recollection and familiarity were affected. In stable MCI 
patients, non-significant medium-size decline compared to controls suggested relatively better 
preserved global forced-choice recognition memory. The slight decline in stable MCI 
patients’ performance may reflect reliance on familiarity to decide among alternatives that 
only partially compensate for impaired recollection 33,34. Among the main memory scores 
(cued recall, recognition memory, recollection and familiarity estimates), recognition memory 
was the only significant predictor that allowed to classify whether a participant belongs to the 
MCI-AD or stable MCI group with 71% accuracy. This extends previous findings showing 
that a recognition memory score was a better predictor of MCI versus controls status than a 
recall score 35. 
 Here the fact that aMCI patients at baseline were in the prodromal stage of AD was 
determined via a neuropsychological and neurological follow-up. The emergence of clinical 
symptoms that are characteristic of typical AD 22 was the criterion for classifying the patients 
as being in the predementia stage at baseline. Currently, the dominant approach to determine 
whether aMCI is due to AD would be to collect biomarker-related information, such as CSF 
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or PET measures of amyloid and tau protein accumulation 36. However, data collection for 
this study started before the advent of amyloid and tau biomarker-related research (2007-
2008). Nevertheless, group comparisons of FDG-PET and grey matter density imaging data 
revealed brain changes in MCI-AD patients which have been typically attributed to MCI due 
to AD, thus comforting the clinical diagnosis 24-26.  
Those aMCI patients who were still diagnosed as aMCI 4 years after inclusion formed 
most probably a very heterogeneous subgroup whose actual aetiology is not known. Among 
them, stability of diagnosis may indicate that they were still early in the course of AD and 
would develop dementia symptoms only later on, or may present with a slowly progressive 
form of AD. Alternatively, patients from the stable MCI group could return to normal if 
memory decline was due to transient affective or sleep difficulties 16,17,37. Others may also 
harbour other types of neurological conditions (such as Parkinson’s disease, supranuclear 
palsy, etc) or psychiatric conditions (e.g., major depression). For the current data, we 
consulted a posteriori the medical records of individuals from the stable MCI group for 
indication about long-term evolution. No information was available for 2 of them. For the 
remaining 21 patients, medical records mentioned the presence of cognitive decline with loss 
of autonomy, suggestive of dementia, in 9 patients. Two others suffered from stroke a few 
years after our study. Five patients still complained about their memory, but did not seem to 
develop dementia in recent records. Finally, 5 subjects appeared to live independently at home 
and did not consult for memory decline anymore. Although to be taken cautiously given the 
lack of rigorous procedure to assess cognitive status in long-term follow-ups, these medical 
information support the idea of heterogeneity in the aetiology of MCI at the time of our study 
for those individuals. 
 The current study has some limitations. First, sample size was small relative to cohort 
studies, so that replication with a larger sample size is needed. Second, the standardized 
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follow-up of the patients was limited to 4 years post-inclusion. This left uncertainty about the 
actual fate of individuals in the stable MCI group. Future work should include longer follow-
up assessment of MCI patients, as this might inform about cognitive profiles leading to rapid 
progression to AD versus to slow decline. Second, since the data were collected, theoretical 
views about familiarity have evolved to better capture its complexity. In particular, it has been 
suggested that there are different forms of familiarity, that only some of them depends on the 
transentorhinal cortex and would be impaired early in the course of AD 11. Future work may 
include longitudinal testing from the preclinical stage to the dementia stage in order to unravel 
the chronological unfolding of recollection and familiarity deficits. 
 In sum, the current medium-term longitudinal study showed that aMCI patients who 
subsequently progressed to Alzheimer’s disease within 4 years of follow-up and who 
presented with hypometabolic and structural patterns typical of early Alzheimer’s disease 
demonstrated impaired recollection and familiarity accuracy. Moreover, poor recognition 
memory best discriminated between MCI-AD and stable MCI patients. For the clinicians, 
these results suggest that observation of impaired recognition memory, or more specifically 
impaired familiarity in a test designed to assess this process, could be taken as an alerting 
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Figure 1. Boxplot of recognition memory performance as a function of group 
 
